Stock comparison
Camurus AB (publ)
CAMX.ST$36.24BHealthcare Market cap, Sector
GSK
GSK$104.47BHealthcare Market cap, Sector
Overall winner
Camurus AB (publ)
CAMX.ST 70 GSK
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
CAMX.ST7wins
0winsGSK
78B
D58
91A
C62
94A
C66
65C
D47
63C
F35
77B
C65
77B
C63
Side-by-side metrics
| Metric | CAMX.ST | GSK |
|---|---|---|
| Market cap | $36.24B | $104.47B Winner |
| P/E (TTM) | 42.6x | 13.0x Winner |
| EV/EBIT | 29.5x | 10.9x Winner |
| ROIC (TTM) | Winner: 17.17% | 13.76% |
| Gross margin | Winner: 93.11% | 72.74% |
| Net margin | Winner: 32.47% | 17.78% |
| Revenue CAGR 5y | Winner: 33.3% | 7.24% |
| EPS CAGR 5y | Winner: 132.79% | 19.78% |
| Debt / Equity | Winner: 0.0x | 1.1x |
| Dividend yield | - | 3.56% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CAMX.ST leads on
- Debt / Equity0.0xvs 1.1x+98%
- EPS CAGR 5y132.79%vs 19.78%+85%
- Revenue CAGR 5y33.3%vs 7.24%+78%
- Net margin32.47%vs 17.78%+45%
GSK leads on
- P/E (TTM)13.0xvs 42.6x+70%
- Market cap$104.47Bvs $36.24B+65%
- EV/EBIT10.9xvs 29.5x+63%
More like CAMX.ST
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.